Sativex <sup>®</sup> as add-on therapy vs. further optimized first-line ANTispastics (SAVANT) in resistant multiple sclerosis spasticity: a double-blind, placebo-controlled randomised clinical trial - Concepedia

Concepedia

Publication | Closed Access

Sativex <sup>®</sup> as add-on therapy vs. further optimized first-line ANTispastics (SAVANT) in resistant multiple sclerosis spasticity: a double-blind, placebo-controlled randomised clinical trial

135

Citations

16

References

2018

Year

Jolana Marková, Ute Essner, Bülent Akmaz, M. Marinelli, C. Trompke, Arnd Lentschat, Carlos Vila

International Journal of Neuroscience

Abstract

Add-on THC:CBD oromucosal spray provided better and clinically relevant improvement of resistant MS spasticity compared with adjusting first-line antispasticity medication alone.

References

	Year	Citations

Page 1